Bayer Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Bayer Healthcare Aktiengesellschaft

Bayer Schering Pharma Ag

Adverio Pharma Gmbh

Bayer Aktiengeselischaft

Other

Bayer Schering Pharma Aktiengellschaft

Johannes-Peter Stasch

Frank Wunder

Andreas Knorr

Volkhart Min-Jian Li

Markus Follmann

Martin Beuck

Gorden Redlich

Peter Fey

Stefan Wohlfeil

Rudolf H Hanko

Stanislav Kazda

Michael Hahn

Karl-Heinz Schlemmer

Thomas Kramer

Walter Hubsch

Dieter Lang

Klaus Dembowsky

Ulrich E Muller

Matthias Muller-Gliemann

Jurgen Dressel

Elke Stahl

Eva-Maria Becker

Alexandros Vakalopoulos

Nils Griebenow

Achim Feurer

Elisabeth Perzborn

Alexander Straub

Joachim Mittendorf

Siegfried Zaiss

Cristina Alonso-Alija

Walter Hübsch

Rolf Jautelat

Niels Lindner

Friederike Stoll

Jens Ackerstaff

Raimund Kast

Stefan Weigand

Dietmar Flubacher

Thomas Lampe

Claudia Hirth-Dietrich

Thomas Krahn

Ingo Hartung

Tobias Marquardt

Ulrich Rosentreter

Thomas Jaetsch

Philipp Buchgraber

Donald Bierer

Klaus Münter

Elke Hartmann

Eva Maria Becker-Pelster

Hilmar Bischoff

Adrian Tersteegen

Dirk Denzer

Andrea Vaupel

Hartmut Schirok

Lisa Dietz

Nicole Diedrichs

Dieter Arlt

Markus Heil

Paul Naab

Wolfgang Bender

Ulrich Niew&ouml;hner

Sherif El Sheikh

Erwin Bischoff

Wahed Ahmed Moradi

Thomas Rölle

Josef Pernerstorfer

Lars Bärfacker

Stephan Bartel

Michael Härter

Hanna Tinel

Joachim Luithle

Stefan Heitmeier

Martina Delbeck

Joerg Keldenich

Rudy Schreiber

Rainer Gross

Rudolf Schohe-Loop

Martin Bechem

Jurgen Stoltefuss

Joachim Schuhmacher

Matthias Schramm

Alexander Hillisch

Siegbert Hebisch

Kerstin Henninger

Ulrich Niewohner

Mario Jeske

Hartmut Beck

Marcus Bauser

Gunter Karig

Eckhard Schwenner

Gunther Kinast

Thomas Schenke

Peter Kolkhof

Heike Heckroth

Mark Jean Gnoth

Joachim Hutter

Hanno Wild

Chantal Fürstner

Jens-Kerim Ergüden

The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Substituted 5-fluoro-1H-pyrazolopyridines and their use

The present application relates to novel 3-phenylpropionic acid derivatives which carry a branched or cyclic alkyl substituent in the 3-position, to processes for their preparation, to their use for the treatment and/or prevention of diseases and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiovascular diseases.

Branched 3-phenylpropionic acid derivatives and their use

The present invention relates to stimulators and activators of soluble guanylate cyclase in combination with an inhibitor of neutral endopeptidase and/or angiotensin AII antagonists and the use thereof for the treatment and/or prophylaxis of cardiovascular disorders, for example heart failure with preserved ejection fraction or heart failure with reduced ejection fraction, renal disorders, for example chronic kidney failure, urological disorders, lung disorders, disorders of the central nervous system, for regulation of cerebral perfusion, for example in the event of vascular cerebral states of dementia, for the treatment and/or prophylaxis of fibrotic disorders and other disease symptoms (e.g. end organ damage affecting the brain, kidney or heart).

Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof

The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides of the general formula (I) to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use

The present application relates to novel heteroaryl-substituted imidazo[1,2-a]pyridines, to processes for preparation thereof, to the use thereof, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular disorders.

Heteroaryl-substituted imidazo[1,2-A]pyridines and their use

The present invention relates to soluble guanylate cyclase (sGC) and to phosphodiesterases (PDEs) and the pharmacology of sGC stimulators, sGC activators and PDE inhibitors (PDE5i) in combination with a) treatments, leading to increased cGMP mobilization, and/or b) tretaments correcting and/or potentiatiating CFTR function, and/or c) treatments currently used as standard of care in Cystic Fibrosis, and/or d) antinflammatory treatments for the preparation of medicaments for the treatment of Cystic Fibrosis (CF) with improved efficacy over methods of treatments already known.

SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis

The present application relates to novel substituted pyrazolo[1,5-a]pyridine-3-carboxamides, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereof

The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs.

Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)

The present application relates to novel substituted pyrazolo[1,5-a]pyridines of the formula (I-A) to processes for preparation thereof, to the use thereof, alone or in combinations, for treatment and/or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially for treatment and/or prophylaxis of cardiovascular disorders.

Substituted pyrazolo[1,5-A]pyridines and their use

The present application relates to novel substituted imidazo[1,2-a]pyrazine carboxamides of general formula (I) to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

N-substituted 8-[(2,6-difluorobenzyl)oxy]-2,6- dimethylimidazo[1,2-a]pyrazin-3-carboxamide derivatives as stimulators of soluble guanylate cyclase (SGC) for the treatment of cardiovascular diseases

The present application relates to novel 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular and cardiopulmonary disorders.

5-aminotetrahydroquinoline-2-carboxylic acids and their use

The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use

Growing community of inventors

Solingen, Germany

Johannes-Peter Stasch